Signs point to sharp rise in drugged driving fatalities

• comments
• 
• 

Fatally injured drivers increasingly test positive for drugs, numbers nearly triple for marijuana in 10-year period

The prevalence of non-alcohol drugs detected in fatally injured drivers in the U.S. has been steadily rising and tripled from 1999 to 2010 for drivers who tested positive for marijuana -- the most commonly detected non-alcohol drug -- suggesting that drugged driving may be playing an increasing role in fatal motor vehicle crashes.

To assess these trends researchers at Columbia University's Mailman School of Public Health examined toxicological testing data from the National Highway Traffic Safety Administration's Fatality Analysis Reporting System and found that of 23,591 drivers who were killed within one hour of a crash, 39.7% tested positive for alcohol and 24.8% for other drugs. While positive results for alcohol remained stable, the prevalence of non-alcohol drugs rose significantly from 16.6% in 1999 to 28.3% in 2010; for marijuana, rates rose from 4.2% to 12.2%. Findings are online in the American Journal of Epidemiology.

This study is based on data from six U.S. states that routinely performed toxicological testing on drivers involved in fatal car crashes -- California, Hawaii, Illinois, New Hampshire, Rhode Island, and West Virginia.

The results showed that alcohol involvement was more prevalent in men (43.6%) than in women (26.1%), but trends were stable for both sexes. In contrast, the substantial increase in the prevalence of marijuana was reported for all age groups and both sexes.

"Although earlier research showed that drug use is associated with impaired driving performance and increased crash risk, trends in narcotic involvement in driver fatalities have been understudied," said Guohua Li, MD, DrPH, professor of Epidemiology and Anesthesiology and director of the Center for Injury Epidemiology and Prevention. "Given the increasing availability of marijuana and the ongoing opioid overdose epidemic, understanding the role of controlled substances in motor vehicle crashes is of significant public health importance."

Joanne Brady, a PhD candidate in epidemiology and the lead author of the study, notes that research from 2007 to 2013 shows an increase in drivers testing positive for marijuana in roadside surveys, as well as drivers involved in fatal crashes in in California and increased use by patients treated in Colorado healthcare settings. "The marked increase in its prevalence as reported in the present study is likely germane to the growing decriminalization of marijuana," noted Ms. Brady. Over the last 17 years, 20 states and Washington, D.C. have enacted legislation, and four more states have legislation pending, to decriminalize marijuana for medical use. "Although each of these states has laws that prohibit driving under the influence of marijuana, it is still conceivable that its decriminalization may result in increases in crashes involving marijuana."

While the study provides evidence that non-alcohol drugs in fatally injured drivers has increased significantly, the authors also note there are some limitations to consider. First, the study is based on data from only six states where this information is captured; secondly, the effects of drugs on driving performance and crash risk vary by drug type, dosage, and the driver's physiological response and tolerance level. Also, it is possible for a driver to test positive for marijuana in the blood up to one week after use.

Therefore, according to Dr. Li, "it is important to interpret the prevalence of non-alcohol drugs reported in this study as an indicator of drug use but not necessarily as a measurement of drug impairment. To control the ongoing epidemic of drugged driving, it is imperative to strengthen and expand drug testing and intervention programs for drivers."

Funding for the study was provided by the National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention (1 R49 CE002096) and by the National Institute on Drug Abuse (R21 DA029670) of the National Institutes of Health.

The authors declare no conflicts of interests.

About Columbia University's Mailman School of Public Health

Founded in 1922, Columbia University's Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of master's and doctoral degree programs. The Mailman School is also home to numerous world-renowned research centers including ICAP (formerly the International Center for AIDS Care and Treatment Programs) and the Center for Infection and Immunity. For more information, please visit https://www.mailman.columbia.edu.